Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.79 |
| ▸ | CDC42 | P60953 | 3/20 | 0.79 |
| ▸ | RAC1 | P63000 | 3/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.79 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketorolac SCHEMBL2221913 | 0.90 | PTGS2 (0.92) | PTGS2CDC42RAC1PTGS1PAK1 | |
| SCHEMBL24807886 | 0.89 | PTGS2 (0.75) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL14892 | 0.88 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL14891 | 0.88 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL23466702 | 0.88 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL4103 | 0.88 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL5301763 | 0.87 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL20553125 | 0.87 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL18797655 | 0.87 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28826490 | 0.87 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4272761-A2 | COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS | Medicon Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4238571-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | OnQuality Pharmaceuticals China Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3818981-A1 | SYNERGIC PHARMACEUTICAL COMPOSITION OF THE ACTIVE ENANTIOMER (S)-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN | Amézcua Amézcua, Federico (MX) | 2021-05-12 | — | — | EP | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2018115984-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-28 | — | — | WO | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2013-05-30 | — | — | US | disclosed |
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | disclosed |
| WO-2009124371-A9 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2010-12-02 | — | — | WO | disclosed |
| WO-2009124371-A2 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2009-10-15 | — | — | WO | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2007088123-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | PTGS2 3821/4885CDC42 404/4885RAC1 1380/4885 |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | PDE6C, PDE6H, PDE6D | PTGS2 101/4885CDC42 1785/4885RAC1 922/4885 |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | PTGS2 18/4885CDC42 1826/4885RAC1 2830/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | PTGS2 18/4885CDC42 1826/4885RAC1 2830/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | PTGS2 18/4885CDC42 1826/4885RAC1 2830/4885 |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | PTGS2 619/4885CDC42 4482/4885RAC1 4845/4885 |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | PTGS2 217/4885CDC42 4577/4885RAC1 3486/4885 |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 440/4885CDC42 2216/4885RAC1 898/4885 |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 489/4885CDC42 1879/4885RAC1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.